Influence of Fixed Combination of Metformin SR and Glimepiride on Carbohydrate, Lipid Metabolism and Arterial Wall Stiffness in Patients with Diabetes Mellitus Type 2

O.S. Larin, K.O. Zuiev, D.H. Kohut

Abstract


To study the effect of hypoglycemic therapy with combination of glimepiride and metformin SR during 12 weeks on carbohydrate and lipid metabolism parameters, changes in the adipokines level in blood plasma and parameters of arterial wall stiffness of large arteries (aorta and its branches), we have observed 30 patients (18 of them — women) with type 2 diabetes mellitus aged 60.10 ± 1.08 years with an average duration of the underlying disease 5.7 ± 0.9 years.
Results. Compared with baseline values, we have marked improvement of carbohydrate metabolism parameters. Thus, HbA1c level decreased by 1.7 % (p < 0.001), fasting glucose — by 22 % (p < 0.001), postprandial blood glucose — by 44 % (p < 0.001). In addition, on the background of therapy, there was an improvement in lipid metabolism: decrease of total cholesterol by 13.2 % (p < 0.01), low-density lipoproteins cholesterol — by 19.3 % (p < 0.01), triglycerides — by 30.6 % (p < 0.05). Changes in plasma adipokine level were noted: decline of adiponectin level from 5.98 ± 0.52 mg/ml to 4.45 ± 0.29 mg/ml (p < 0.01), as well as trend to increase of leptin level in blood plasma from 14.6 ± 2.3 ng/ml to 18.12 ± 2.90 ng/ml (p > 0.05). Changes in pulse wave velocity in the aorta and aortic augmentation index were statistically non-significant (p > 0.05). Changes in anthropometric parameters (body mass index, waist and hip circumference), as well as the total amount of adipose tissue, as defined by impedancemetry, were statistically non-significant (p > 0.05).
Conclusions. Combined hypoglycemic therapy with glimepiride and metformin SR for 12 weeks resulted in a statistically significant improvement of carbohydrate and lipid metabolism, had no effect on anthropometric parameters and the total amount of adipose tissue, prevented the progression of arteriosclerosis of large vessels according to the indicators of arterial wall stiffness.


Keywords


type 2 diabetes mellitus; metformin; glimepiride; leptin; adiponectin; arterial wall stiffness; pulse wave velocity in the aorta; augmentation index

References


The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — 358. — P. 2560-2572.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. — 2008. — 358. — P. 2545-2559.

Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. — 2009. — Vol. 360. — P. 129-139.

Scirica B.M., Bhatt D.L., Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus // N. Engl. J. Med. — 2013. — Vol. 369 (14). — Р. 1317-1326.

White W.B., Cannon C.P., Heller S.R. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes // N. Engl. J. Med. — 2013. — Vol. 369 (14). — P. 1327-1335.

The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia // N. Engl. J. Med. — 2012. — Vol. 367. — P. 319-328.

Ismail-Beigi F., Moghissi E., Tiktin M. et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials // Ann. Intern. Med. — 2011. — Vol. 154. — Р. 554-559.

Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. — 2015. — Vol. 38. — Р. 140-149.

Monami M., Luzzi C., Chiasserini V. et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin // Diabetes Metab. Res. Rev. — 2006. — Vol.22. — Р. 477-482.

www.dtu.ox.ac.uk/Homacalculator/index.php‎

Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling // Diabetes Care. — 2004. — Vol. 27, № 6. — P. 1487-1495.

Müller G., Satoh Y. et al. Extrapancreatic effects of sulfonylureas — a comparison between glimepiride and conventional sulfonylureas // Diabetes Res. Clin. Pract. — 1995. — Vol. 28. — P. 115-137.

Robertson R.P., Harmon J., Tran P.O. et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes // Diabetes. — 2004. — Vol. 53, Suppl. 1. — Р. 119-124.

Korytkowski M., Thomas A., Reid L. et al. Glimepiride improves both first and second phases of insulin secretion intype 2 diabetes // Diabetes Care. — 2002. — Vol. 25(9). — P. 1607-1611.

Shakuto S., Oshima K., Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits // Atherosclerosis. — 2005. — Vol. 182(2). — P. 209-217.

Shimpi R.D., Patil P.H. et al. Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 diabetes mellitus // International Journal of Pharm. Tech. Research. — 2009. — Vol. 1. — Р. 50-61.

Weitgasser R., Lechleitner M., Luger A. et al. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study // Diabetes Research and Clinical Practice. — 2003. — Vol. 61, Issue 1. — P. 13-19.

Arechavaleta R., Seck T., Chen Y. et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial // Diabetes, Obesity and Metabolism. — 2011. — Vol. 13, № 2. — P. 160-168.

Зуєв К.О., Паньків В.І., Юзвенко Т.Ю., Когут Д.Г. Показники жорсткості великих артерій у пацієнтів із цукровим діабетом 2-го типу з ожирінням та артеріальною гіпертензією залежно від типу цукрознижувальної терапії // Ендокринологія. — 2014. — Т. 19, № 2. — С. 111-118.

Полторак В.В., Горшунська М.Ю., Красова Н.С. Адипонектин та цукровий діабет 2-го типу (патогенетичні аспекти як підґрунтя для оптимізації антидіабетичної фармакотерапії) [Текст] / В.В. Полторак // Международный эндокринологический журнал. — 2014. — № 5(61). — С. 95-104.

Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes // N. Engl. J. Med. — 2007. — Vol. 356. — Р. 2457-2471.




DOI: https://doi.org/10.22141/2224-0721.3.67.2015.75269

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru